NCT06823232View on ClinicalTrials.gov

A Study on the Substance Balance of [14C]XY0206 in Healthy Adult Chinese Men

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

December 5, 2024

Study Completion Date

December 5, 2024

Conditions
Metabolism of Radioactive Substances
Interventions
DRUG

[14C]XY0206

On the morning of the day of medication (D1), the subject took \[14C\] XY0206 suspension orally on an empty stomach (containing approximately 37.5 mg/100 µ Ci \[14C\] XY0206).

Trial Locations (1)

102200

Beijing Gaobo Hospital, Life Science Park Road, Changping District, Beijing, Beijing

All Listed Sponsors
lead

Shijiazhuang Yiling Pharmaceutical Co. Ltd

INDUSTRY

NCT06823232 - A Study on the Substance Balance of [14C]XY0206 in Healthy Adult Chinese Men | Biotech Hunter | Biotech Hunter